Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | APEX1 | P27695 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | DUT | P33316 | 6/20 | 0.39 |
| ▸ | NAAA | Q02083 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 3/20 | 0.37 |
| ▸ | CA2 | P00918 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | EP300 | Q09472 | 1/20 | 0.35 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26035122 | 1.00 | TSHR (0.43) | TSHRPOLBAPEX1HTTTDP1 | |
| SCHEMBL26035127 | 1.00 | TSHR (0.43) | TSHRPOLBAPEX1HTTTDP1 | |
| SCHEMBL26035117 | 1.00 | TSHR (0.43) | TSHRPOLBAPEX1HTTTDP1 | |
| SCHEMBL26035119 | 1.00 | TSHR (0.43) | TSHRPOLBAPEX1HTTTDP1 | |
| SCHEMBL24205062 | 0.95 | DUT (0.43) | TSHRPOLBAPEX1HTTTDP1 | |
| SCHEMBL24205050 | 0.89 | TSHR (0.44) | TSHRPOLBAPEX1HTTTDP1 | |
| SCHEMBL24205051 | 0.89 | TSHR (0.44) | TSHRPOLBAPEX1HTTTDP1 | |
| SCHEMBL26035157 | 0.89 | TSHR (0.44) | TSHRPOLBAPEX1HTTTDP1 | |
| SCHEMBL24205341 | 0.89 | TSHR (0.44) | TSHRPOLBAPEX1HTTTDP1 | |
| SCHEMBL26035155 | 0.89 | TSHR (0.44) | TSHRPOLBAPEX1HTTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230273455-A1 | OPTICALLY ACTIVE DEVICES | JOHNSON & JOHNSON SURGICAL VISION INC (US) | 2023-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230273455-A1 | OPTICALLY ACTIVE DEVICES | PDE6C, PDE6A, PDE6D | TSHR 4592/4885POLB 1376/4885APEX1 133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.